Saturday, September 06, 2025 11:55:35 AM
Iovance, the future of cancer treatment is now: https://www.iovance.com/
The products: https://www.amtagvi.com/ https://www.iovance.com/products/
The corporate deck: https://ir.iovance.com/static-files/f808d866-804d-4a80-9d4b-b702474ac1ef
An older corporate deck for comparison: https://ir.iovance.com/static-files/a829b645-572a-407d-8a9c-325a07d6e3f3
The pipeline and the future: https://www.iovance.com/clinical-pipeline/
Do your own due diligence (it helps you to avoid all the misinformation that gets posted on message boards): https://ir.iovance.com/
GL to IOVA shareholders.
The products: https://www.amtagvi.com/ https://www.iovance.com/products/
The corporate deck: https://ir.iovance.com/static-files/f808d866-804d-4a80-9d4b-b702474ac1ef
An older corporate deck for comparison: https://ir.iovance.com/static-files/a829b645-572a-407d-8a9c-325a07d6e3f3
The pipeline and the future: https://www.iovance.com/clinical-pipeline/
Do your own due diligence (it helps you to avoid all the misinformation that gets posted on message boards): https://ir.iovance.com/
GL to IOVA shareholders.
Recent IOVA News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001 • GlobeNewswire Inc. • 06/01/2026 11:30:00 AM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/22/2026 09:15:00 PM
- Iovance Biotherapeutics to Present at Upcoming Conference • GlobeNewswire Inc. • 05/21/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 01:18:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:16:23 PM
- Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates • GlobeNewswire Inc. • 05/07/2026 11:05:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/01/2026 09:00:21 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 09:05:17 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 09:01:20 PM
- Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 • GlobeNewswire Inc. • 04/27/2026 12:01:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/17/2026 09:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 09:01:25 PM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (US) • 04/01/2026 12:49:00 AM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (Canada) • 04/01/2026 12:49:00 AM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (US) • 03/24/2026 02:00:00 PM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (Canada) • 03/24/2026 02:00:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2026 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 09:25:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:02:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:12 PM
